Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. to Retire from its Board after Sixteen Years of Service
26 Enero 2024 - 7:00AM
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical
technology company focused on the development and commercialization
of innovative, minimally invasive solutions for patients with
obstructive sleep apnea (OSA), today announced the retirement of
Jerry C. Griffin, M.D., from its Board of Directors, to be
effective at the conclusion of the Company’s Annual Meeting of
Stockholders scheduled to occur on May 2, 2024.
“After sixteen years of service, we announce the retirement of
Dr. Griffin from our Board of Directors. His contributions to our
Board and organization are innumerable and we are grateful for the
dedication and direction he provided to our organization,” said Tim
Herbert, President and Chief Executive Officer of Inspire Medical
Systems. “I want to personally thank Jerry for his years at
Inspire, his invaluable expertise, guidance and partnership
contributed to Inspire growing from a startup to a medical device
company with over 60,000 patients treated, one thousand employees,
and $600 million in annual revenue.”
Dr. Griffin has served on the Inspire Board of Directors since
2008 and was one of the original board members, having joined
Inspire prior to the initial Series A financing. He most recently
served on the Nominating and Corporate Governance Committee. In
December 2023, the Inspire Board appointed another esteemed
physician and seasoned medical device executive with the
appointment of Myriam J. Curet, M.D. to its Board of Directors. Dr.
Curet currently serves as Executive Vice President and Chief
Medical Officer of Intuitive Surgical.
About Inspire Medical Systems
Inspire is a medical technology company focused on the
development and commercialization of innovative, minimally invasive
solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved
neurostimulation technology that provides a safe and effective
treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit
www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and important factors could cause
actual results to differ materially from those anticipated,
including the factors identified under the captions “Risk Factors”
and “Management's Discussion and Analysis of Financial Condition
and Results of Operations” in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 filed with the SEC, and as
such factors may be updated from time to time in our other filings
with the SEC, which are accessible on the SEC’s website at
www.sec.gov and the Investors page of our website at
www.inspiresleep.com. Forward-looking statements speak only as of
the date they are made, and we undertake no obligation to update
them in light of new information or future events.
Investor and Media ContactEzgi YagciVice
President, Investor
Relationsezgiyagci@inspiresleep.com617-549-2443
Inspire Medical Systems (NYSE:INSP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Inspire Medical Systems (NYSE:INSP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024